AAPGV - Ascentage Pharma Group International Operating profit before deduction of amortization
Ascentage Pharma Group is automating the search for oncoprotein inhibitors through robotic molecular design, eliminating manual labor. The cash EBITDA trend reflects the current financial result of operations, where the indicator value stands at 0.00. The company is minimizing lab technician involvement in tests by implementing software robots to process targeted therapy data sets and perform molecular screening.
Ascentage Pharma (AAPGV) - metric breakdowns and financial figures
- stock quotes and analyst forecast:
- market capitalization statistics:
- shareholders' equity book value data:
- company total debt and liquidity indicators:
Debt to Capital Ascentage Pharma Group|AAPGV - Long-Term Debt to Capital|Short-Term Debt to Capital Ascentage Pharma Group International|AAPGV - Company Debts|Debts to Net Assets Ascentage Pharma|AAPGV - Company Long-Term Debts|Company Current Liabilities Ascentage Pharma|Immediate Liquidity ascentage.com
- business earnings and investment ratios data:
AAPGV - Company Net Income|Net Profit Forecast Ascentage Pharma Group|AAPGV - Price to Earnings Ratio|Market Cap to Future Earnings Ratio ascentage.com|AAPGV - PEG Multiple|EV/EBITDA Multiple Ascentage Pharma|AAPGV - Operating profit EBITDA|Net earnings per share for the trailing year Ascentage Pharma|AAPGV - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months ascentage.com|AAPGV - Net earnings per share growth this year|Expected earnings per share trend next year Ascentage Pharma Group
Analysis of all company metrics:AAPGV Ascentage
The investment attractiveness of Ascentage Pharma Group (AAPGV) is based on the international management's ability to monetize oncology developments in the Chinese and US markets. An analysis of absolute EBITDA allows for an assessment of the real efficiency of the operating cycle, excluding debt load and asset depreciation, confirming the business's financial stability amid the Fed's tight monetary policy.
Who Ascentage Pharma Group competes with
Income before deduction of interest, taxes and amortization ONC|Halozyme Therapeutics - Operating profit EBITDA|revmed.com (RVMD) - Operating profit before deduction of amortization|AAPG (Ascentage Pharma) - Operating profit before deduction of amortization|CG Oncology Inc (CGON) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization UroGen|BCAX: Income before deduction of interest, taxes and amortization|Operating profit EBITDA PSNL|ERAS - Profit before interest, taxes and amortization|Operating profit EBITDA DCTH (Delcath Systems)|Operating profit EBITDA Y-mAbs Therapeutics Inc YMAB|AURA - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Candel Therapeutics CADL|ARAY: Operating profit EBITDA|Operating profit before deduction of amortization SELLAS Life Sciences Group|ACTU (Actuate Therapeutics) - Operating profit EBITDA|Profit before interest, taxes and amortization Citius Oncology Inc. CTOR|Profit before payment of interest, taxes and amortization TuHURA Biosciences, Inc. (HURA)|Protara Tx - Operating profit before amortization|Fate Therapeutics, Inc. - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization WHWK (Aadi Bioscience, Inc.)|TScan - Operating profit EBITDA|CSBR - Operating profit EBITDA|XBIT: Operating profit EBITDA|Operating profit before depreciation charges CEL-SCI CVM|OSTX (OS Therapies Incorporated) - Operating profit EBITDA|Profit before interest, taxes and amortization radiopharmtheranostics.com RADX|Operating profit before deduction of amortization ARTV (Artiva Biotherapeutics, Inc.)|ANL (adlainortye.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Veru Pharma VERU|TPST (Tempest Therapeutics Corp) - Profit before deduction of interest, taxes, depreciation and amortization|Xilio - Operating profit EBITDA|Income before deduction of interest, taxes and amortization RENB (Renovaro Inc.)|MURA: Operating profit EBITDA|Kairos Pharma (KAPA) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization OnKure Therapeutics, Inc.|GDTC: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Curis, Inc. (CRIS)|Operating profit before deduction of amortization apollomicsinc.com APLM|Operating profit EBITDA THAR (Tharimmune)|Operating profit EBITDA Advanced Biomed Inc. ADVB|GNPX: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization CLDI (Calidi Biotherapeutics)|SBFM: Operating profit EBITDA|Operating profit before depreciation charges Xenetic Biosciences, Inc. XBIO|Profit before payment of interest, taxes and amortization Salarius Pharmaceuticals, Inc.|PPBT: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization American Oncology Network (AONC)|BGNE - Profit before interest, taxes and amortization|Checkpoint Therapeutics - Operating profit before deduction of amortization|Operating profit EBITDA elevationoncology.com ELEV|ICAD - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization IKNA|NTBL: Operating profit EBITDA|Viracta Therapeutics, Inc. (VIRX) - Operating profit EBITDA|MOR (MorphoSys AG) - Operating profit EBITDA|Operating profit EBITDA nayabiosciences.com
